This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.Need a new registration confirmation email? Click here

Warner Chilcott Reaches New 52-Week High (WCRX)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK (
TheStreet) --
Warner Chilcott (Nasdaq:
WCRX) hit a new 52-week high Tuesday as it is currently trading at $20.53, above its previous 52-week high of $20.51 with 17.4 million shares traded as of 1:45 p.m. ET. Average volume has been five million shares over the past 30 days.

Warner Chilcott has a market cap of $4.82 billion and is part of the health care sector and drugs industry. Shares are down 2.1% year to date as of the close of trading on Monday.

Warner Chilcott Public Limited Company, a specialty pharmaceutical company, engages in the development, manufacture, promotion, and franchise of branded pharmaceutical products focusing on the women's healthcare, gastroenterology, urology, and dermatology markets. The company has a P/E ratio of 13.3, below the S&P 500 P/E ratio of 17.7.

EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates Warner Chilcott as a
hold. Among the primary strengths of the company is its expanding profit margins over time. At the same time, however, we also find weaknesses including weak operating cash flow and a generally disappointing performance in the stock itself. You can view the full
Warner Chilcott Ratings Report.